Named one of the “ Top 10 Apps That Could Save Your Life” in the Jan. 22, 2012 issue of Parade Magazine, Health Discovery Corporation (OTCBB: HDVY), the molecular diagnostics company that launched MelApp in July 2011, the first SVM-based image analysis iPhone app for melanoma risk assessment, is pleased to announce it has received a record number of downloads in the days following the article. The national exposure resulted in an increase of more than 3,100 percent in daily downloads since the article was issued. “We are beyond excited about the recognition MelApp received in Parade Magazine and the success that we have seen as a result of the coverage,” said Stephen D. Barnhill, M.D., chairman and CEO of Health Discovery Corporation. “It’s always great to be recognized for MelApp by industry peers, but to be included in such a powerful article in a highly-reputable national publication such as Parade is quite an honor.” Launched in July 2011, MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze an uploaded image. Using the camera feature of their iPhone, iPad or iPod Touch, MelApp users can capture an image of their mole or freckle to be analyzed; use the app’s zoom and/or tracing functionality to accurately identify the outline of their mole; then upload it to MelApp’s system for assessment. The app was validated using an image database licensed from Johns Hopkins University Medical Center and can deliver a risk analysis of user’s photographed skin lesions within seconds. In addition, MelApp can use the iPhone GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical follow-up. The full article from Parade Magazine featuring MelApp can be found at http://www.parade.com/news/intelligence-report/2012/01/22-10-apps-that-could-save-your-life.html. About MelApp & Health Discovery Corporation MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze the uploaded image. MelApp was validated using an image database licensed from Johns Hopkins University Medical Center and uses the iPhone camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. The app can use the iPhone GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical follow-up. MelApp by Health Discovery Corporation was launched at a special limited time introductory price of $1.99 and is available in the iTunes App Store. For more complete details, visit http://www.melapp.net, http://www.facebook.com/MelApp or http://twitter.com/#!/SafeHealthApps. Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.